Pegilodecakin clinical trials
Also written LY3500518 and AM0010.
How each study uses pegilodecakin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2017 | 3 |
| 2018 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses pegilodecakin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)CompletedPhase 1Eli Lilly and CompanyNCT03267732Written as Pegilodecakin
- A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04194892Written as Pegilodecakin
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT02009449Written as Pegilodecakin
- A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)CompletedPhase 1Eli Lilly and CompanyNCT03381547Written as Pegilodecakin
- Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung CancerTerminatedPhase 2Eli Lilly and CompanyNCT03382899Written as Pegilodecakin
- Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic CancerCompletedPhase 3Eli Lilly and CompanyNCT02923921Written as Pegilodecakin
- Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung CancerTerminatedPhase 2Eli Lilly and CompanyNCT03382912Written as Pegilodecakin
Codes
What other systems call pegilodecakin · ClinicalTrials.gg INT015154
- MeSH (NLM) C000632591pegilodecakinOne source ClinicalTrials.gov
- UNII (FDA) 5Z9850I25FPEGILODECAKINOne source FDA
- NCI Thesaurus C113295PegilodecakinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632591 | pegilodecakin | One source ClinicalTrials.gov |
| UNII (FDA) | 5Z9850I25F | PEGILODECAKIN | One source FDA |
| NCI Thesaurus | C113295 | Pegilodecakin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.